SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63388 357 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
61586About CBAY and Avoro. So I finally looked up “pre funded warrants” (yes, I tenderickerickson51/31/2023
61585Wow. As of 9/30/2022 13F Avoro already owned 10,300,000 shares, 12% + ownership.sysiphus11/31/2023
61584CBAY shares. Guess who bought the CBAY shares... I feel better now! Captain BDavidoff91/30/2023
61583OT writing for the masses… “This is why Technical Writers are paid well…” I waerickerickson-1/30/2023
61582The next bit of P2 data will be coming in Q3 this year and the P3 studies wont rstockdoc7711/29/2023
61581I’m not so much worried that it works or not; I think something seems to be goinjargonweary21/29/2023
61580Given that an ALZ drug barely needs to work to get approval, I'm less concerallatwwk11/28/2023
61579You make an excellent point about SPA and the fact that this status brings FDA ijargonweary21/28/2023
61578At one time I wondered if SavaDx was being used for screening in Phase 3, but itghettogoulash-1/28/2023
61577I'm not concerned about Phase 3 screening or any other facet of the trials, ghettogoulash31/28/2023
61576commentary on SAVA screening criteria: firstly, I was appalled at the slow pacescorman111/27/2023
61575Yes, water under the bridge and another lesson in biotech investing. It is easijargonweary21/27/2023
61574I agree Jargonweary, also, the data seemed to go south near the end of the trailidahoranch121/27/2023
61573Yep, I have told a lot of people over the years that small cap biotech investingjargonweary31/27/2023
61572Legit concern jargon. Amplified by having less-than-stellar CEO. Of course, weallatwwk-1/27/2023
61571When it comes to how to think about SAVA and Simufilam I am frankly haunted by mjargonweary41/27/2023
61570Nothing really new, but one positive take w/some interesting comments by others.Stanley Lake 92-1/27/2023
61569This is why Technical Writers are paid well. Scientists are often just that, andEMU2-1/27/2023
61568Wow, that was some digging. And yikes!! Years ago, my Dad had all sorts of thinallatwwk31/26/2023
61567Sorry about all the posts. The Trial Summary led me astray. It seems that Joe Spghettogoulash21/26/2023
61566I'm guessing that was just the inclusion criteria for the original 2b study ghettogoulash-1/26/2023
61565Then again, this is clearly worded as an inclusion criteria: a ratio, a specificghettogoulash31/26/2023
61564I just received an email from Mr. Barbier. My conclusion: the screening of theghettogoulash21/26/2023
61563So let's just say the elimination of CSF requirements occurred midway betweeghettogoulash31/26/2023
61562This brings up an interesting point I have been trying to make about Sava's ghettogoulash-1/26/2023
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News